Richmond Pharmacology has formed an Expert Regulatory Advisory Board to strengthen its support for clinical trial sponsors navigating complex and evolving regulatory environments. The new advisory board brings together former senior regulators and industry leaders with deep experience across UK, EU and international authorities and regulatory strategy. It will work closely with Richmond’s clinical and regulatory teams to embed practical regulatory insight early in drug development planning and trial delivery.

The board’s expertise spans scientific advice engagement, first-in-human and complex trial design, advanced therapy development, inspection readiness and global regulatory strategy. Chaired by Dr Lisa Campbell, Director of Regulatory Strategy at Richmond Pharmacology and former senior assessor at the UK regulator MHRA, and supported by Vice Chair James Rickard, the initiative aims to help sponsors reduce risk and accelerate development timelines by ensuring regulatory considerations are integrated from the outset. Richmond says the board reflects its ongoing investment in regulatory excellence and its commitment to combining real-world regulatory experience with its clinical trial delivery capabilities to support innovative drug programmes more effectively.